Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL961908 | 0.83 | ALDH1A1 (0.48) | ALDH1A1MAPTCYP1A2CYP3A4SMN1; SMN2 | |
| SCHEMBL961910 | 0.83 | ALDH1A1 (0.48) | ALDH1A1MAPTCYP1A2CYP3A4SMN1; SMN2 | |
| SCHEMBL963049 | 0.77 | ERN1 (0.42) | ALDH1A1MAPTERN1CYP1A2HPGD | |
| SCHEMBL964621 | 0.75 | ALDH1A1 (0.48) | ALDH1A1MAPTCYP1A2CYP3A4HPGD | |
| SCHEMBL27772666 | 0.74 | ALDH1A1 (0.41) | ALDH1A1MAPTERN1CYP1A2CYP3A4 | |
| SCHEMBL964719 | 0.74 | SIRT2 (0.46) | ALDH1A1MAPTCYP2A6CYP1A2CYP3A4 | |
| SCHEMBL15635469 | 0.73 | CYP2A6 (0.41) | ALDH1A1MAPTCYP2A6ERN1HPGD | |
| SCHEMBL964202 | 0.72 | ALDH1A1 (0.42) | ALDH1A1MAPTCYP1A2CYP3A4HPGD | |
| SCHEMBL964204 | 0.72 | ALDH1A1 (0.42) | ALDH1A1MAPTCYP1A2CYP3A4HPGD | |
| SCHEMBL19209467 | 0.72 | ALDH1A1 (0.49) | ALDH1A1MAPTERN1CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | ALDH1A1 421/4885MAPT 4343/4885CYP2A6 347/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | ALDH1A1 821/4885MAPT 4720/4885CYP2A6 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.